Cardama, GA, Alonso, DF et al. Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. Critical Reviews in Oncology/ Hematology; 124:29-36, 2018.
Guo, Y, Kenney, SR, et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol. Cancer Ther; 14(10), 2015.
Guo, Y, Kenney, SR, et al. A Novel Pharmacologic Activity of Ketorolac for Therapeutic Beneﬁt in Ovarian Cancer Patients. Clin Cancer Res; 21(22):5064-5072, 2015.
Ji, J, Feng, X, et al. Rac1 is correlated with aggressiveness and a potential therapeutic target for gastric cancer. Int. J. of Oncol; 46:1343-1353, 2015.
Leng, R, Liao, G, et al. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome. Med Oncol; 32:28, 2015.
Kazanietz, MG and Caloca, MJ. The Rac GTPase in Cancer: From Old Concepts to New Paradigms. Cancer Res; 77(20), 2017.
Maldonado, M and Dharmawardhane, S. Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res; 78(12), 2018.
Porter, PA, Papioannouy, A, and Malliri, A. Deregulation of Rho GTPases in cancer. Small GTPases; 7(3):123-128, 2016.
Yue, X, Zhang, C, et al. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes and Dev; 31:1641–1654, 2017.
Zhou, Y, Liao, Q, et al. Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer. J. Cancer; 7: 2100-2109, 2017.
Copyright © 2019 Revere Pharmaceuticals. All Rights Reserved.
Design and development by RainCastle Communications